Related Experiment Video
Updated: Jul 2, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience
Andrew Y Li1, Farin Kamangar2, Noa G Holtzman3
1University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Abstract:
Circulating plasma cells (CPCs) are detected in most multiple myeloma (MM) patients, both at diagnosis and on relapse. A small subset, plasma cell leukemia (PCL), represents a different biology and has a poor prognosis. In this retrospective analysis, we evaluated patients with primary (pPCL, n = 35) or secondary (sPCL, n = 49), with ≥5% CPCs and a smaller subset with lower CPCs of 1-4% (n = 20). The median age was 61 years; 45% were men and 54% were Black. High-risk cytogenetics were found in 87% and extramedullary disease in 47%. For the entire cohort, 75% received a proteasome inhibitor, 70% chemotherapy, 54% an immunomodulatory drug, 24% a daratumumab-based regimen and 26% an autologous stem cell transplant (ASCT). The treatments marginally improved the overall survival (OS) for pPCL vs. sPCL (13 vs. 3.5 months p = 0.002). However, the 5-year survival for the whole cohort was dismal at 11%. High-risk cytogenetics, low platelets, extramedullary disease and high LDH were independently associated with poor outcomes. Further research is urgently needed to expand the treatment options and improve the outcomes in PCL.
Insights
Plasma cell leukemia (PCL) patients have circulating plasma cells (CPCs) and a poor prognosis. Despite various treatments, the 5-year survival remains low at 11%, highlighting the urgent need for better therapeutic options.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Circulating plasma cells (CPCs) are common in multiple myeloma (MM), but plasma cell leukemia (PCL) signifies a distinct, aggressive subtype.
- PCL presents as primary (pPCL) or secondary (sPCL) and is associated with poor patient outcomes.
Purpose of the Study:
- To evaluate the clinical characteristics, treatment patterns, and survival outcomes of patients with plasma cell leukemia (PCL).
- To identify factors associated with poor prognosis in PCL.
Main Methods:
- Retrospective analysis of patients with primary or secondary PCL, including those with ≥5% and 1-4% circulating plasma cells (CPCs).
- Data collected on patient demographics, cytogenetics, disease characteristics, treatments received (proteasome inhibitors, chemotherapy, immunomodulatory drugs, daratumumab, ASCT), and survival.
Main Results:
- The cohort (n=104) had a median age of 61, with 47% having extramedullary disease and 87% high-risk cytogenetics.
- While treatments like proteasome inhibitors and chemotherapy were common, overall survival was poor, with a 5-year survival of 11%.
- Primary PCL showed marginally better survival (13 months) than secondary PCL (3.5 months). High-risk cytogenetics, low platelets, extramedullary disease, and high LDH were linked to worse outcomes.
Conclusions:
- Plasma cell leukemia (PCL) remains a challenging hematologic malignancy with dismal survival rates despite current therapies.
- Urgent development of novel treatment strategies is required to improve outcomes for PCL patients.
- Identifying prognostic factors aids in risk stratification and understanding the disease's aggressive nature.
